From Functional Food to Therapeutic Prospect: Mechanistic Study of Gypenoside XVII in HeLa Cells

TL;DR

This study explores how Gypenoside XVII, a natural compound, can inhibit cervical cancer cell growth and induce apoptosis, suggesting its potential as a functional food ingredient and anticancer agent.

Contribution

The study identifies Gypenoside XVII's novel anticancer mechanisms in HeLa cells, including cell-cycle arrest and activation of apoptotic pathways.

Findings

Gypenoside XVII caused dose-dependent growth inhibition and apoptotic morphology in HeLa cells.

The compound induced G0/G1 cell-cycle arrest and activated caspase-9 and caspase-8 pathways.

It shows promise as a natural anticancer lead and functional-food ingredient.

Abstract

Cervical cancer remains a prominent cause of cancer-related mortality among women worldwide because of chronic infection with high-risk human papillomavirus (HPV) and disparate access to prevention and treatment. The current research evaluates the anticancer activity of Gypenoside XVII, a bioactive saponin of Gynostemma pentaphyllum, in HeLa cells as a model of cervical cancer. MTT, Annexin V-PI, and Hoechst 33342 assays showed dose-dependent growth inhibition with typical apoptotic morphology. Flow cytometry revealed G0/G1 cell-cycle arrest, while pathway interrogation revealed participation of mitochondrial and death-receptor cascades, in agreement with caspase-9 and caspase-8 activation, respectively. Collectively, these findings position Gypenoside XVII as a natural-product bioactive with potential both as an anticancer lead and as a functional-food ingredient, deserving of further preclinical development.

Figures